Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B M Brenner

Showing results (331-340 of 342) with videos related to

Pageof 35
Sort By:
The American Journal of Physiology|June 1, 1995
ROMK inwardly rectifying ATP-sensitive K+ channel. II. Cloning and distribution of alternative formsM A Boim, K Ho, M E Shuck, et al.
The Journal of Clinical Investigation|May 1, 1976
Permselectivity of the glomerular capillary wall. Studies of experimental glomerulonephritis in the rat using dextran sulfateC M Bennett, R J Glassock, R L Chang, et al.
Circulation Research|May 1, 1984
Renal and systemic hemodynamic responses to intravenous infusion of leukotriene C4 in the ratK F Badr, C Baylis, J M Pfeffer, et al.
Diabetologia|August 6, 2005
Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) studyG Boner, M E Cooper, K McCarroll, et al.
The Journal of Clinical Investigation|May 1, 1976
Permselectivity of of the glomerular capillary wall. Studies of experimental glomerulonephritis in the rat using neutral dextranR L Chang, W M Deen, C R Robertson, et al.
Kidney International|June 9, 2000
Renal allograft protection with losartan in Fisher-->Lewis rats: hemodynamics, macrophages, and cytokinesF Ziai, H Nagano, M Kusaka, et al.
Ugeskrift for Laeger|October 17, 2001
[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy]H H Parving, B M Brenner, M E Cooper, et al.
The New England Journal of Medicine|September 22, 2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyB M Brenner, M E Cooper, D de Zeeuw, et al.
Diabetes, Obesity & Metabolism|October 30, 2015
Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trialH J L Heerspink, T Ninomiya, F Persson, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|April 23, 2002
The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)B M Brenner, M E Cooper, D de Zeeuw, et al.
Pageof 35

Showing results (331-340 of 342) with videos related to

Sort By:
Pageof 35
The American Journal of Physiology|June 1, 1995
ROMK inwardly rectifying ATP-sensitive K+ channel. II. Cloning and distribution of alternative formsM A Boim, K Ho, M E Shuck, et al.
The Journal of Clinical Investigation|May 1, 1976
Permselectivity of the glomerular capillary wall. Studies of experimental glomerulonephritis in the rat using dextran sulfateC M Bennett, R J Glassock, R L Chang, et al.
Circulation Research|May 1, 1984
Renal and systemic hemodynamic responses to intravenous infusion of leukotriene C4 in the ratK F Badr, C Baylis, J M Pfeffer, et al.
Diabetologia|August 6, 2005
Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) studyG Boner, M E Cooper, K McCarroll, et al.
The Journal of Clinical Investigation|May 1, 1976
Permselectivity of of the glomerular capillary wall. Studies of experimental glomerulonephritis in the rat using neutral dextranR L Chang, W M Deen, C R Robertson, et al.
Kidney International|June 9, 2000
Renal allograft protection with losartan in Fisher-->Lewis rats: hemodynamics, macrophages, and cytokinesF Ziai, H Nagano, M Kusaka, et al.
Ugeskrift for Laeger|October 17, 2001
[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy]H H Parving, B M Brenner, M E Cooper, et al.
The New England Journal of Medicine|September 22, 2001
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyB M Brenner, M E Cooper, D de Zeeuw, et al.
Diabetes, Obesity & Metabolism|October 30, 2015
Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trialH J L Heerspink, T Ninomiya, F Persson, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|April 23, 2002
The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)B M Brenner, M E Cooper, D de Zeeuw, et al.
Pageof 35